AstraZeneca fends off Pfizer with new growth plan

May 6, 2014 by Sylvia Hui
An exterior view of the Two Kingdom Street building which houses the headquarters of AstraZeneca, in the Paddington area of London, Friday, May 2, 2014. The board of pharmaceutical company AstraZeneca on Friday rejected drug maker Pfizer's sweetened takeover offer. Pfizer earlier in the day said it is offering 50 pounds ($84) a share in cash and stock, a 7.3 increase on a previous bid. The offer values AstraZeneca at $106 billion. (AP Photo/Matt Dunham)

AstraZeneca on Tuesday outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival Pfizer.

In a statement, AstraZeneca said investors would share the benefits of a "strong and consistent revenue growth" that would see annual sales rise to more than $45 billion by 2023 from $25.7 billion last year.

The U.K.-based company on Friday spurned Pfizer's third acquisition proposal, this time for about $106 billion. AstraZeneca PLC, the No. 8 drugmaker, called that inadequate and said the potentially lucrative "pipeline" of new drugs it is developing would be disrupted by a takeover.

AstraZeneca's revenues last year fell 6 percent but the company said Tuesday that under its new management and strategy it is now "repositioned for a return to growth."

"AstraZeneca is completing its transformation, and now has the right size, focus and team to deliver on one of the most exciting pipelines in the pharmaceutical industry," said Chief Executive Pascal Soriot. "We are continuing to create significant value for shareholders from our independent strategy."

Pfizer said last week it was considering its options. If the deal succeeds, it would be the biggest takeover in British corporate history. Many politicians fear it could mean big job cuts and a loss of stature in the country's science sector.

On Tuesday, Business Secretary Vince Cable told lawmakers he will not rule out intervening in any formal bid by Pfizer to buy AstraZeneca, although he stressed that the shareholders of both companies make the ultimate decision.

"We see the future of the U.K. as a knowledge economy, not as a tax haven," he said, referring to concerns that Pfizer could benefit from tax advantages should it acquire AstraZeneca.

The British government can intervene in mergers or takeovers in cases where national security, competition concerns or national financial stability, among other issues, are at stake.

Explore further: AstraZeneca profits and revenues fall

Related Stories

AstraZeneca profits and revenues fall

October 31, 2013

British drugmaker AstraZeneca reported Thursday that third-quarter net profit fell 17.5 percent to 1.25 billion pounds ($200 billion) as the patents on older drugs expired.

AstraZeneca pays $4.1 billion for diabetes buyout (Update)

December 19, 2013

Anglo-Swedish drugmaker AstraZeneca PLC will buy out Bristol-Myers Squibb Co.'s stake in their partnership to develop and sell diabetes drugs in a deal worth $4.1 billion—seizing an opportunity to serve the projected explosion ...

Probe-hit GlaxoSmithKline announces profits slump

April 30, 2014

GlaxoSmithKline, the British drugs giant facing a series of probes into alleged staff corruption, announced sliding profits on Wednesday, one week after unveiling a group makeover.

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.